Ten years ago, the phrase 'families after cancer1 for most women would have been an oxymoron ifcontemplated at all. Today, due to the impressive rise in young female cancer survivors, this is not only awell-used phrase, but also an issue that women increasingly want addressed. As the lexicon is beingestablished, the boundaries are expanding to encompass the fertility needs of childhood cancer survivors forwhom fertility-conserving options are limited. The role of the emerging oncofertility specialist is to navigatethrough the available options and provide individualized counseling to patients. To provide this kind ofauthoritative information to women in different age brackets, with different treatment regimens, it isnecessary to evaluate the reproductive axis and its response to cancer treatment in a rigorous manner. Theability to recruit patients through the large National Physicians Cooperative (P30B) will provide sufficientpower to correlate treatment and outcome data in a comprehensive and thorough manner.
In Specific Aim 1, we will develop combinatorial analytical methods and a predictive algorithm to assess the Risk of ImpendingPremature Ovarian Failure (RIPOF, pronounced rip off) in young women treated with chemotherapeutics fortheir cancers. These data will improve information exchange between the provider and the patient about therisk and timeframe of impending premature ovarian failure. We will also use the established murine ovarianculture system to test a broad panel of chemotherapeutics and establish endpoints that can be used torapidly assess the likely fertility impact of any new or existing drugs that are introduced into the oncologists'arsenal (Specific Aim 2). Therefore, the relative toxicity of new chemotherapeutic agents on in vitro folliclesurvival and maturation (in vitro risk, IVR) will be investigated. Finally, the major goal of the project is todevelop methods to grow immature human ovarian follicles into the mature, fertilizable stage (Specific Aim3). We will translate recent breakthroughs at the interface of material science and reproductive biology intoclinically-proven technology that can provide additional fertility options to those who may lose fertility due tocancer treatment.
Showing the most recent 10 out of 37 publications
